Adachi Y, Yamamoto H, Itoh F, Hinoda Y, Okada Y, Imai K. 1999. Contribution of matrilysin (MMP-7) to the metastatic pathway of human colorectal cancers Gut, 45, 252-258. Asakura H. 1998. Ulcerative colitis and intestinal bleeding. Nihon Rinsho, 56, 2354-2359. Atreya R, Mudter J, Finotto S, Müllberg J, Jostock T, Wirtz S, Schütz M, Bartsch B, Holtmann M, Becker C, et al. 2000. Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: evidence in Crohn disease and experimental colitis in vivo. Nature Medicine, 6, 583- 588. Baugh M D, Perry M J, Hollander A P, Davies D R, Cross S S, Lobo A J, Taylor C J, Evans G S. 1999. Matrix metalloproteinase levels are elevated in inflammatory bowel disease. Gastroenterology, 117, 814-822 Brown K A, Back S J, Ruchelli E D, Markowitz J, Mascarenhas M, Verma R, Piccoli D A, Baldassano R N. 2002. Lamina propria and circulating interleukin-6 in newly diagnosed pediatric inflammatory bowel disease patients The American Journal of Gastroenterology, 97, 2603-2608 Cooper H S, Murthy S N, Shah R S, Sedergran D J. 1993. Clinicopathologic study of dextran sulfate sodium experimental murine colitis. Laboratory Investigation, 69, 238-249 Crohn B B, Rosenberg H. 1925. The sigmoidoscopic picture of chronic ulcerative colitis (non-specific). Americn Journal of Medical Sciences, 170, 220-227 Eaden J A, Abrams K R, Mayberry J F. 2001. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut, 48, 526-535 Fahlgren A, Hammarström S, Danielsson A, Hammarström M L. 2003. Increased expression of antimicrobial peptides and lysozyme in colonic epithelial cells of patients with ulcerative colitis. Clinical and Experimental Immunology, 131, 90-101 Grosse Hülsewiesche A, Grosse G, Kevenoglu M, Niedobitek F, Volkheimer G. 1989. Lysozyme and lactoferrin in normal and inflammatory changes of the gastric mucosa. Zeitschriftfur Gastroenterology, 27, 714- 721. Heuschkel R B, MacDonald T T, Monteleone G, Bajaj- Elliott M, Smith J A, Pender S L. 2000. Imbalance of stromelysin-1 and TIMP-1 in the mucosal lesions of children with inflammatory bowel disease Gut, 47, 57- 62. Holtkamp W, Stollberg T, Reis H E. 1995. Serum interleukin-6 is related to disease activity but not disease specificity in inflammatory bowel disease Journal of Clinical Gastroenterology, 20, 123-126 Hyams J S, Fitzgerald J E, Treem W R, Wyzga N, Kreutzer D L. 1993. Relationship of functional and antigenic interleukin 6 to disease activity in inflammatory bowel disease. Gastroenterology, 104, 1285-1292 Klockars M, Reitamo S. 1975. Tissue distribution of lysozyme in man. The Journal of Histochemistry and Cytochemistry, 23, 932-940 von Lampe B, Barthel B, Coupland S E, Riecken E O, Rosewicz S. 2000. Differential expression of matrix metalloproteinases and their tissue inhibitors in colon mucosa of patients with inflammatory bowel disease. Gut, 47, 63-73 Louis E, Belaiche J, van Kemseke C, Franchimont D, de Groote D, Gueenen V, Mary J Y. 1997. A high serum concentration of interleukin-6 is predictive of relapse in quiescent Crohn’s disease European Journal of Gastroenterology & Hepatology, 9, 939-944 Mitsuyama K, Sata M, Rose-John S. 2006. Interleukin-6 trans-signaling in inflammatory bowel disease Cytokine & Growth Factor Reviews, 17, 451-461 Miyazaki K, Hattori Y, Umenishi F, Yasumitsu H, Umeda M. 1990. Purification and characterization of extracellular matrix-degrading metalloproteinase, matrin (pump-1), secreted from human rectal carcinoma cell line Cancer Research, 50, 7758-7764. Montero C, Erlandsen S L. 1978. Immunocytochemical and histochemical studies on intestinal epithelial cells producing both lysozyme and mucosubstance. The Anatomical Record, 190, 127-141 Mudter J, Neurath M F. 2007. Apoptosis of T cells and the control of inflammatory bowel disease: therapeutic implications. Gut, 56, 293-303 Mudter J, Neurath M F. 2007. IL-6 signaling in inflammatory bowel disease: pathophysiological role and clinical relevance Inflammatory Bowel Diseases, 13, 1016-1023. Neurath M F, Finotto S. 2009. Translating inflammatory bowel disease research into clinical medicine. Immunity, 31, 357-361 Newell K J, Witty J P, Rodgers W H, Matrisian L M. 1994. Expression and localization of matrix-degrading metalloproteinases during colorectal tumorigenesis. Molecular Carcinogenesis, 10, 199-206 Owczarek D, Cibor D, Szczepanek M, Mach T. 2009. Biological therapy of inflammatory bowel disease. Polskie Archiwum Medycyny Wewnetrznej, 119, 84-88 Reinisch W, Gasché C, Tillinger W, Wyatt J, Lichtenberger C, Willheim M, Dejaco C, Waldhör T, Bakos S, Vogelsang H, et al. 1999. Clinical relevance of serum interleukin-6 in Crohn’s disease: single point measurements, therapy monitoring, and prediction of clinical relapse The American Journal of Gastroenterology, 94, 2156-2164. Saarialho-Kere U K, Vaalamo M, Puolakkainen P, Airola K, Parks W C, Karjalainen-Lindsberg M L. 1996. Enhanced expression of matrilysin, collagenase, and stromelysin-1 in gastrointestinal ulcers The American Journal of Pathology, 148, 519-526. Sava G, Bergamo A, Capozzi I, Clerici K, Pacor S, Gagliardi R, Giacomello E, Zacchigna M, di Luca G, Boccu E. 1996. Stimulation of GALT and activation of mesenteric lymph node lymphocytes by a modified lysozyme in CBA mice with MCa mammary carcinoma. Journal of Experimental Therapeutics & Oncology, 1, 342-349 Shanahan F, Bernstein C N. 2009. The evolving epidemiology of inflammatory bowel disease. Current Opinion in Gastroenterology, 25, 301-305 Stallmach A, Chan C C, Ecker KW, Feifel G, Herbst H, Schuppan D, Zeitz M. 2000. Comparable expression of matrix metalloproteinases 1 and 2 in pouchitis and ulcerative colitis. Gut, 47, 415-422 Umehara Y, Kudo M, Nakaoka R, Kawasaki T, Shiomi M. 2006. Serum proinflammatory cytokines and adhesion molecules in ulcerative colitis. Hepato-Gastroenterology, 53, 879-882 Vaalamo M, Karjalainen-Lindsberg M L, Puolakkainen P, Kere J, Saarialho-Kere U. 1998. Distinct expression profiles of stromelysin-2 (MMP-10), collagenase-3 (MMP-13), macrophage metalloelastase (MMP-12), and tissue inhibitor of metalloproteinases-3 (TIMP- 3) in intestinal ulcerations The American Journal of Pathology, 152, 1005-1014. Wilson C L, Matrisian L M. 1996. Matrilysin: An epithelial matrix metalloproteinase with potentially novel functions. The International Journal of Biochemistry & Cell Biology, 28, 123-136 Wilson C L, Matrisian L M. 1998. Matrilysin. In: Parks W C, Mecham R P, eds., Matrix Metalloproteinases. Academic Press, New York. pp. 149-184 Wilson C L, Ouellette A J, Satchell D P, Ayabe T, López- Boado Y S, Stratman J L, Hultgren S J, Matrisian L M, Parks W C. 1999. Regulation of intestinal alpha-defensin activation by the metalloproteinase matrilysin in innate host defense. Science, 286, 113-117 Woessner Jr J F, Taplin C J. 1988. Purification and properties of a small latent matrix metalloproteinase of the rat uterus. The Journal of Biological Chemistry, 263, 16918-16925 Yamamoto H, Itoh F, Adachi Y, Iku S, Fukushima H, Horiuchi S, Min Y, Sasaki S, Imai K. 2000. Matrix metalloproteinase matrilysin in cancers of the digestive organs. Tumor Research, 35, 1-12 |